Source: https://www.wipo.int/amc/en/domains/decisions/html/2006/d2006-0305.html
Timestamp: 2019-04-20 08:24:47+00:00

Document:
Complainant is Lilly ICOS LLC, (“Complainant”), a limited liability company organized under the laws of the State of Delaware with a principal place of business in Wilmington, Delaware, represented by Baker & Daniels, United States of America. Complainant is a joint venture between ICOS Corporation and Eli Lilly and Company.
Respondent is Kevin Adelman (“Respondent”), Orlando, Florida, United States of America.
The domain name at issue is <generic-cialis-prescription.com> (the “Domain Name”). The registrar is Tucows, Inc. (the “Registrar”), located in Toronto, Ontario, Canada.
On March 10, 2006, the WIPO Arbitration and Mediation Center (the “Center”) received a copy of the Complaint via email. On March 13, 2006 the Center sent an Acknowledgment of Receipt of Complaint to Complainant. On March�14, 2006, the Center received the hardcopies of the Complaint. Complainant paid the required fee.
On March 13, 2006, after the Center sent a Request for Verification to the Registrar requesting verification of registration data, the Registrar confirmed, inter alia, that it is the registrar of the Domain Name and that the Domain Name is registered in Respondent’s name.
The Center verified that the Complaint satisfied the formal requirements of the ICANN Uniform Domain Name Dispute Resolution Policy (the “Policy”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”).
On March 20, 2006, the Center sent a Notification of Complaint and Commencement of Administrative Proceeding to Respondent together with copies of the Complaint, with a copy to Complainant. This notification was sent by the methods required under paragraph 2(a) of the Rules.
On April 10, 2006, the Center advised Respondent that it was in default for failing to file its Response. No Response has been received.
On April 19, 2006 after the Center received a completed and signed Statement of Acceptance and Declaration of Impartiality and Independence from Richard W. Page (the “Panel”), the Center notified the parties of the appointment of a single-member panel consisting of the Panel.
On June 17, 1999, Complainant filed for registration of the CIALIS trademark (the “Mark”) with the United States Patent and Trademark Office. On June 10, 2003, the CIALIS Mark was registered on the principal register (No. 2,274,589). Complainant’s decision to use the CIALIS Mark to identify its pharmaceutical product was made public in July 2001. Complainant began selling pharmaceutical products identified by the CIALIS Mark on January 22, 2003, in the European Union, followed soon thereafter by sales in Australia and New Zealand. Complainant began sales in the United States in November 2003. In total, Complainant has obtained more the eighty-seven (87) registrations for the CIALIS Mark covering more than 117 countries and the CIALIS Mark is the subject of pending registration applications filed by Complainant in twenty-four (24) countries. Additionally, in the year 2004, Complainant spent approximately $39 million to market and to sell its CIALIS brand product worldwide. United States sales of the CIALIS brand product totaled more than $206 million and worldwide sales of CIALIS brand product were in excess of $550 million.
Complainant also has an Internet presence, primarily through the website accessed by the domain name <cialis.com>, that it uses to advertise and provide information regarding its pharmaceutical product. The <cialis.com> domain name was registered by Eli Lilly and Company on August 10, 1999. Complainant has used this domain name to identify a website since at least June 2001.
Respondent registered the Domain Name on November 23, 2004.
i. Complainant contends that it has registrations of the CIALIS Mark, that its trademark registrations are valid and subsisting, and that they serve as prima facie evidence of its ownership and the validity of the CIALIS Mark. 15 U.S.C. � 1115. Complainant further alleges that its registrations are incontestable and conclusive evidence of its exclusive right to use the CIALIS Mark in connection with the stated goods. 15 U.S.C. �� 1065 and 115(b).
Respondent cannot demonstrate rights or legitimate interest in the Domain Name under paragraph 4(c)(i) because he has not made use, or demonstrable preparations to use, the Domain Name in connection with the bona fide offering of goods or services. Complainant alleges that the only apparent purpose for Respondent’s use of the Domain Name is to drive Internet users to a website offering generic Cialis or competing products. Complainant further alleges that Respondent is receiving a fee for his click-through traffic.
Respondent cannot demonstrate rights or legitimate interests in the Domain Name under paragraph 4(c)(ii) because it is not known by the Domain Name. Respondent has no connection or affiliation with Complainant, and has not received any license or consent, express or implied, to use the CIALIS Mark in a domain name or in any other manner.
Complainant alleges that the facts stated satisfy the elements of bad faith as stated in paragraph 4(b)(iv) of the Policy by using the domain name, to intentionally attract, for commercial gain, Internet users to his website, by creating a likelihood of confusion with Complainant’s CIALIS Mark as to the source, sponsorship, affiliation, or endorsement of Respondent’s website.
Respondent has failed to respond to Complainant’s allegations.
Because both Complainant and Respondent are domiciled in the United States and United States courts have recent experience with similar disputes, to the extent that it would assist the Panel in determining whether Complainant has met its burden as established by paragraph 4(a) of the Policy, the Panel shall look to rules and principles of law set out in decisions of the courts of the United States. Tribeca Film Center, Inc. v. Brusasco-Mackenzie, WIPO Case No. D2000-1772.
A respondent is not obliged to participate in a domain name dispute proceeding, but if it were to fail to do so, asserted facts that are not unreasonable would be taken as true and respondent would be subject to the inferences that flow naturally from the information provided by complainant: See Reuters Limited v. Global Net 2000, Inc., WIPO Case No. D2000-0441. See also Hewlett-Packard Company v. Full System, NAF Case No. FA 0094637; David G. Cook v. This Domain is For Sale, NAF Case No. FA0094957 and Gorstew Jamaica and Unique Vacations, Inc. v. Travel Concierge, NAF Case No. FA0094925.
Complainant contends that it has registrations of the CIALIS Mark, that its trademark registrations are valid and subsisting, and that they serve as prima facie evidence of its ownership and the validity of the CIALIS Mark. 15 U.S.C. � 1115. Complainant further alleges that its registrations are incontestable and conclusive evidence of its exclusive right to use the CIALIS Mark in connection with the stated goods. 15 U.S.C. �� 1065 and 115(b).
Respondent has not contested the assertions by Complainant that it has valid registrations of the CIALIS Mark. Therefore, the Panel finds that Complainant, for purposes of this proceeding, has enforceable rights in the CIALIS Mark.
Complainant further contends that the Domain Name is identical with and confusingly similar to the trademark pursuant to the Policy, paragraph 4(a)(i).
Respondent has not contested the assertions by Complainant that the Domain Name is confusingly similar to the CIALIS Mark.
As numerous courts and prior UDRP panels have recognized, the incorporation of a trademark in its entirety is sufficient to establish that a domain name is identical or confusingly similar to complainant’s registered mark. See Paccar Inc. v. Telescan Technologies, L.L.C., 115 F. Supp. 772 (E.D. Mich. 2000) (finding that <peterbuilttrucks.com>, <kenworthtrucks.com> and similar domain names are not appreciably different from the trademarks PETERBUILT and KENWORTH); Quixar Investments Inc. v. Dennis Hoffman, WIPO Case No. D2000-0253, (finding that QUIXTAR and <quixtarmortgage.com> are legally identical). The addition of other descriptive terms in the domain name does not affect a finding that the domain name is identical or confusingly similar to the complainant’s registered trademark.
The Panel notes that the entirety of the CIALIS Mark is included in the Domain Name. The only additional words are “generic” and “prescription” which are both descriptive in the drug industry.
Therefore, the Panel finds that the Domain Name is confusingly similar to the CIALIS Mark pursuant to the Policy, paragraph 4(a)(i).
Paragraph 4(a)(ii) requires Complainant to prove that Respondent has no rights to or legitimate interests in the Domain Name. Once Complainant establishes a prima facie showing that none of the three circumstances establishing legitimate interests or rights apply, the burden of production on this factor shifts to Respondent to rebut the showing. The burden of proof, however, remains with Complainant to prove each of the three elements of paragraph 4(a). See Document Technologies, Inc. v. International Electronic Communications, Inc., WIPO Case No. D2000-0270.
Complainant alleges that Respondent cannot demonstrate rights or legitimate interest in the Domain Name (1) because Respondent’s driving Internet users to his website with a Domain Name confusingly similar to the CIALIS Mark and receiving a click-through fee is not a bona fide offering of goods or services, (2) Respondent is not known by the Domain Name, and (3) Respondent is not making a legitimate noncommercial or fair use of the Domain Name without the intent to derive commercial gain.
Complainant has sustained its burden of coming forward with evidence that Respondent lacks rights to or legitimate interests in the Domain Name.
Respondent has failed to respond to Complainant’s allegations, and the file contains no evidence that the use of the Domain Name meets the elements for any of the nonexclusive methods provided for in the Policy, paragraph 4(c). Therefore, the Panel finds that Respondent has no rights or legitimate interest in the Domain Name pursuant to the Policy, paragraph 4(a)(ii).
Complainant alleges that the facts stated satisfy the elements of bad faith as stated in paragraph 4(b)(iv) of the Policy by Respondent using the Domain Name, to intentionally attract, for commercial gain, Internet users to his website, by creating a likelihood of confusion with Complainant’s CIALIS Mark as to the source, sponsorship, affiliation, or endorsement of Respondent’s website.
The Panel found above that the Domain Name is confusingly similar to the CIALIS Mark pursuant to the Policy, paragraph 4(a)(i). Respondent has not denied the allegations that he registered and is using the Domain Name for commercial purposes. Additionally, the circumstances of this file support the conclusion that Respondent is engaged in commercial activity.
The Panel finds that this evidence is sufficient to establish the necessary elements of bad faith under the Policy, paragraph 4(b)(iv).
The Panelist concludes (a) that the Domain Name <generic-cialis-prescription.com> is confusingly similar to Complainant’s registered CIALIS Mark, (b) that Respondent has no rights or legitimate interest in the Domain Name and (c) that Respondent registered and used the Domain Name in bad faith. Therefore, pursuant to paragraphs 4(i) of the Policy and 15 of the Rules, the Panel orders that the Domain Name be transferred to Complainant.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.